Promising clinical benefit rates in advanced cancers alongside potential biomarker correlation in a phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy
Authors
Bono, P.Pasanen, A.
Verlingue, L.
de Jonge, M. J. A.
de Miguel, M. J.
Skytta, T.
Iivanainen, S.
Shetty, S.
Ma, Y. T.
Graham, Donna
Arora, S. P.
Jaakkola, P.
Yap, C.
Jalkanen, S.
Hollmen, M.
Koivunen, J.
Minchom, A. R.
Affiliation
Terveystalo Hospital and University of Helsinki, Helsinki, FinlandIssue Date
2022
Metadata
Show full item recordCitation
Bono P, Pasanen A, Verlingue L, de Jonge MJA, de Miguel MJ, Skytta T, et al. Promising clinical benefit rates in advanced cancers alongside potential biomarker correlation in a phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680300868.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.2645Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.2645Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.2645